Global
English
Global
English
Global
English
Poland
polski
Czechia
Český
Italy
Italiano
Kazakhstan
Қазақ
Slovakia
Slovenský
Spain
Español
Ukraine
Українськa
Uzbekistan
Ўзбекча
Vietnam
Tiếng việt
Adamed across the globe
Global development
A consistently implemented development strategy based on two pillars – innovation and international expansion – has made the pharmaceutical and biotechnology company Adamed a renowned global brand.
The international expansion of our company is based on two business models
in Poland
representative offices
available around the world
on a global scale
Investments in Asia
At the end of 2017, Adamed acquired a majority stake in the local pharmaceutical company Davipharm, and in April 2023 the purchase transaction of the remaining 30 percent of shares was closed - thus Adamed became the sole owner of the Vietnamese company.
This investment is aimed at strengthening Davipharm's market position by introducing EU-GMP standards in the plant and allowing the company to compete with high-quality imported drugs at prices affordable to Vietnamese patients.
Through the purchase transaction 100 percent of shares in Davipharm, Adamed is building a strong platform for further dynamic expansion in the Asia-Pacific area.
Ecupharma acquisition
In 2019, Adamed purchased a block of shares in the Italian company Ecupharma. We formed a strategic partnership with the company to support Adamed’s expansion in the Italian market of cardiac medications, and ultimately also in otherareas of therapy.
Ecupharma is a rapidly growing pharmaceutical company active in the fields of neuropsychiatry and urology. Its product portfolio addresses the needs of people with chronic ailments. The company consistently builds its market standing with the support of its loyal customers. Similarly to Adamed, the company also focuses on health conditions affecting the elderly, seeking to respond to contemporary demographic challenges.
Spanish expansion – the Riells plant
In January 2026, Adamed Pharma signed a preliminary agreement with Sanofi to acquire a manufacturing plant in Riells i Viabrea, Spain. This is another step in the implementation of the company's international growth strategy. The goal is to increase production capacity, diversify manufacturing sites, and strengthen drug security in Europe.
The plant has been operating for over 50 years, specializes in the production of tablets and capsules, and manufactures approximately 75 million packs of medicines annually, reaching 77 countries worldwide. Upon completion of the acquisition, the facility will become one of the key points in Adamed's international production network, focused on high-volume medicines, mainly for the European market.
Adamed plans further investments in production modernization, infrastructure, and logistics, as well as the gradual introduction of its own product portfolio into manufacturing.